Juravinski Hospital

Hamilton, Ontario L8V 5C2

4 studies enrolling now · 13 studies all time

What they study most

Acute Kidney Injury, Atrial Fibrillation, Breast Cancer, COVID-19, Community-acquired Pneumonia, Influenza, COVID-19, Corona Virus Infection, Covid19, Critically Ill, Hemorrhage, Hepatocellular Carcinoma, Hip Fractures, Invasive Mould Infection

Studies at this site

• Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy — Recruiting now
• Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress — Recruiting now
• HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial — Recruiting now
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia — Recruiting now
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy — Running, not enrolling
• A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) — Completed
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) — Running, not enrolling
• Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial) — Completed
• CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) — Stopped early
• Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE) — Completed
• Perioperative Anticoagulant Use for Surgery Evaluation Study — Completed
• Frequency of Screening and SBT Technique Trial — Status unconfirmed
• Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed